If you or someone in your household has narcolepsy, you know how much this condition can affect daily life. People with narcolepsy have fragmented nighttime sleep and extreme sleepiness during the day ...

SAN DIEGO -- AXS-12 (reboxetine), an investigational treatment for narcolepsy, reduced weekly cataplexy attacks and in some cases provided complete remission, the phase III SYMPHONY study showed. From ...

77% of narcolepsy type 1 patients continue to experience cataplexy attacks despite being treated 64% of narcolepsy type 1 patients continue to experience excessive daytime sleepiness, as assessed by ...

On Tuesday, Axsome Therapeutics Inc (NASDAQ:AXSM) said AXS-12 statistically significantly reduced the frequency of cataplexy attacks compared to placebo (p=0.017, primary endpoint) in Phase 3 ENCORE ...

AXS-12 statistically significantly reduced cataplexy attacks compared to placebo (p=0.018, primary endpoint) AXS-12 achieved statistically significant remission of cataplexy compared to placebo ...

The now 20-year-old was diagnosed with narcolepsy as a teen and uses her platform to inform people about her experience Despite her condition, she just won her second World Championship title Rylie ...

Axsome's AXS-12 met its primary endpoint in a Phase 3 study, significantly reducing cataplexy attacks in narcolepsy patients, positioning it for an NDA submission. The narcolepsy market is substantial ...

Axsome Therapeutics (NASDAQ:AXSM) said a long-term Phase 3 study of its drug AXS-12 for the treatment of narcolepsy with cataplexy has met its primary endpoint. The study showed AXS-12 was able to ...

Aaron Schokman is a member of the Sleep Health Foundation’s Consumer Reference Council. He has also received funding from the American Academy of Sleep Medicine Foundation for narcolepsy related ...

Monday, Axsome Therapeutics Inc (NASDAQ:AXSM) released data from the SYMPHONY Phase 3 trial of AXS-12 (reboxetine) in narcolepsy patients. Narcolepsy is a sleep disorder that makes people very drowsy ...